Retatrutide entered the spotlight after its Phase 2 results were published in leading medical journals. Here is a research-focused summary of what those studies reported.
Phase 2 obesity findings
In a 48-week Phase 2 trial in adults with obesity, participants on the highest studied dose experienced mean body-weight reductions that were the largest reported for any compound in this class at the time of publication. Effects were dose-dependent — higher studied doses tracked with larger changes.
Metabolic markers
Beyond weight, trials examined glycemic markers and other metabolic endpoints, with researchers reporting improvements consistent with the compound’s triple mechanism.
Tolerability
As with other GLP peptides, the most commonly reported adverse events were gastrointestinal — nausea, diarrhea, and related effects — and were generally described as dose-related and most common during dose escalation. See our side-effects overview.
Take our 60-second quiz for a personalized recommendation and unlock 35% off your first order of USA-made, COA-verified GLP.
Retatrutide remains investigational and in ongoing later-phase study. For context on the mechanism behind these results, read how retatrutide works.
For research and educational use only. The information here is not medical advice and RDAmd products are not intended to diagnose, treat, cure, or prevent any disease or for human consumption. Retatrutide is an investigational compound and is not approved by the FDA. Always consult a qualified professional.
